南北方最新报告流感样病例百分比均高于过去3年同期 线上药物成交额近期激增

Core Insights - The flu cases in China have significantly increased as winter approaches, with ILI% reported at 6.7% in southern provinces and 7.0% in northern provinces, both higher than the previous week and the same period in 2022, 2023, and 2024 [1] Group 1: Flu Case Statistics - The ILI% for southern provinces is reported at 6.7% and for northern provinces at 7.0%, indicating a rise in flu cases [1] - The reported ILI% is higher than the levels observed in the previous week and the same weeks in the past three years [1] Group 2: Sales Data for Flu Medications - JD Health reported a significant increase in sales of flu medications, with orders for antipyretic and analgesic drugs growing over 4.5 times compared to October [1] - The sales of the drug "Sufuda" increased by over 14 times, while the sales of "Dafei" and "Kewai" also saw growth exceeding 9 times [1] - Alibaba Health indicated that from November 10 to November 23, the number of buyers for antiviral flu medications surged by over 500% compared to the previous month [1] Group 3: Home Testing Services - Major e-commerce platforms are competing for customer traffic through home testing services, with Taobao Shanguo and Alibaba Health launching a "home flash test" service for respiratory virus and bacteria detection [1] - JD Daojia reported that from November 14 to November 20, the order volume for home sampling of respiratory bacteria and virus testing services increased nearly 100% compared to the previous week [2]